-+ 0.00%
-+ 0.00%
-+ 0.00%
Hansoh Pharma says NMPA grants priority review for HS-20093 in small cell lung cancer
Share
Listen to the news
Hansoh Pharma says NMPA grants priority review for HS-20093 in small cell lung cancer
  • Hansoh’s HS-20093 (risvutatug rezetecan) for small cell lung cancer entered China NMPA priority review on Aug. 21, 2026.
  • Filing targets patients whose disease progressed following prior platinum-based chemotherapy.
  • Submission supported by positive results from the Phase III ARTEMIS-008 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12328908), on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending